#video-generation

Eli Lilly moved into selective degradation of pathogenic autoantibodies with a deal worth up to $2.875B. Elsewhere, open-weight AI models grew markedly in scale, ChatGPT advertising reached a $1B annualized run rate, and data from hundreds of thousands of businesses showed AI use climbing without an apparent employment shock so far.

Sebastian Raschka published a comprehensive 2025 LLM review covering DeepSeek R1, RLVR, inference-time scaling, and 2026 predictions, while Simon Willison released his annual year-in-LLMs retrospective. On the pharma front, NIH Director Jay Bhattacharya confirmed that DEI-related grants restored under a court order will not be renewed in 2026, even as NIH began reviewing thousands of delayed proposals and funded 135 on the first day. Novo Nordisk priced its newly approved Wegovy pill below Eli Lilly's competing obesity drug in a direct-to-consumer push. On the economy side, researchers across 16 countries found that the post-1980 labor share decline is driven by the composition of capital, not its quantity, and building more structures may reverse it.